Your Comprehensive Guide to Macular Degeneration Drugs in the US

Published: May 4, 2026 · 4 min read

Macular degeneration, especially age-related macular degeneration (AMD), is a leading cause of vision loss among older adults in the United States. Medical innovations have made drug therapies available that can slow disease progression and, in some cases, help patients maintain better vision for longer.

These treatments target abnormal blood vessel growth and leakage under the retina that cause vision deterioration. Selecting the right medication depends on the type of AMD (wet or dry), disease stage, insurance coverage, and your doctor’s recommendation.

Types of Macular Degeneration Drugs

There are two primary types of macular degeneration—wet AMD and dry AMD—each with different treatment approaches.

Wet AMD Treatments

Anti-VEGF (Vascular Endothelial Growth Factor) drugs are the standard treatment for wet AMD. These medications block the growth of abnormal blood vessels in the retina.

• Lucentis (ranibizumab)

• Eylea (aflibercept)

• Avastin (bevacizumab, used off-label)

Dry AMD Treatments

Dry AMD has fewer drug options. Management often includes AREDS2 vitamins. For certain advanced cases such as geographic atrophy, FDA-approved treatments include:

• Syfovre (pegcetacoplan)

• Izervay (avacincaptad pegol)

Leading Drug Manufacturers

Several pharmaceutical companies play a major role in the US macular degeneration drug market:

• Regeneron Pharmaceuticals – Manufacturer of Eylea for wet AMD.

• Genentech (Roche subsidiary) – Producer of Lucentis and supplier of Avastin.

• Apellis Pharmaceuticals – Developer of Syfovre for geographic atrophy.

• Iveric Bio (acquired by Astellas) – Launched Izervay for geographic atrophy.

These companies continue investing in research and innovation in eye disease management.

How to Choose the Right Drug

Consult your ophthalmologist when selecting a macular degeneration drug. Factors influencing your decision may include:

• Diagnosis (wet vs. dry AMD)

• Drug effectiveness

• Injection frequency

• Side effect profile

• Insurance coverage and copay requirements

Some medications require monthly injections, while others involve fewer visits. Insurance plans may have preferred drugs, so reviewing your benefits is important.

Bring your medication list and insurance information to appointments to help coordinate care with your eye specialist and pharmacy.

Drug Costs in the US

Brand-name macular degeneration drugs can be expensive:

• Eylea: Approximately $1,800–$2,200 per injection (Medicare Part B coverage available)

• Lucentis: Approximately $1,800–$2,200 per injection (Medicare Part B coverage available)

• Avastin: Approximately $50–$150 per injection (off-label use; Medicare Part B coverage available)

• Syfovre: Around $2,200 per injection (Medicare Part B coverage available)

• Izervay: Around $2,200 per injection (Medicare Part B coverage available)

Costs may be partially or fully covered by insurance, Medicare, or manufacturer assistance programs depending on eligibility.

Pros and Cons of Anti-VEGF Therapy

Advantages

• Effective in slowing vision loss

• FDA-approved and well-studied

• Insurance support often available

• Patient assistance programs may reduce out-of-pocket costs

Disadvantages

• Requires recurring eye injections

• High upfront cost for brand-name drugs

• Potential side effects such as mild discomfort, redness, increased intraocular pressure, and rare infection (endophthalmitis)

• May require long-term treatment

Consumer Tips

• Explore manufacturer copay assistance and patient support programs.

• Stay consistent with your injection schedule to prevent rapid vision decline.

• Discuss side effects and expected outcomes with your doctor.

• Consider transportation options for frequent appointments.

Conclusion

Macular degeneration no longer means inevitable blindness. With early diagnosis, appropriate medication, and consistent care from a trusted ophthalmologist, many patients can slow disease progression and preserve vision. Ongoing pharmaceutical innovation continues to offer new hope for people living with AMD.

FAQ

What are the most common drugs used for wet macular degeneration?

Anti-VEGF agents including Eylea (aflibercept), Lucentis (ranibizumab), and Avastin (bevacizumab, used off-label).

How much do macular degeneration drugs cost in the US?

Brand-name injections such as Eylea and Lucentis cost around $1,800–$2,200 per dose. Avastin may cost $50–$150 per injection when used off-label.

Are these drugs covered by Medicare or insurance?

Most anti-VEGF drugs are covered under Medicare Part B and many private insurance plans, though patients may still owe a portion depending on coverage.

What are possible side effects of anti-VEGF injections?

Possible side effects include mild eye discomfort, redness, elevated intraocular pressure, and rarely, infection.

Can patients switch between different drugs?

Switching may be possible based on response, side effects, or insurance coverage, but should always be discussed with a retinal specialist.